Literature DB >> 33382671

The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020.

Kathleen Dooling, Mona Marin, Megan Wallace, Nancy McClung, Mary Chamberland, Grace M Lee, H Keipp Talbot, José R Romero, Beth P Bell, Sara E Oliver.   

Abstract

The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use.† On December 1, ACIP recommended that 1) health care personnel§ and 2) residents of long-term care facilities¶ be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (2). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non-health care workers), and that in Phase 1c, persons aged 65-74 years, persons aged 16-64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP's recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33382671      PMCID: PMC9191902          DOI: 10.15585/mmwr.mm695152e2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   35.301


On December 22, 2020, this report was posted online as an MMWR Early Release. The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) () and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use. On December 1, ACIP recommended that 1) health care personnel and 2) residents of long-term care facilities be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non–health care workers), and that in Phase 1c, persons aged 65–74 years, persons aged 16–64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP’s recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology. Since June 2020, ACIP has convened 10 public meetings to review evidence-based information pertaining to COVID-19 vaccines, including initial allocation of COVID-19 vaccine supplies. To inform policy options for ACIP, the COVID-19 Vaccines Work Group, comprising experts in infectious diseases, vaccinology, vaccine safety, public health, and ethics, held 28 meetings to review data regarding vaccine candidates, COVID-19 surveillance, modeling of allocation scenarios, and vaccination program implementation issues. The Work Group also considered the relevant scientific literature, including ethical principles related to vaccine allocation in the setting of limited supply. Following ACIP’s interim recommendation for vaccine allocation in Phase 1a (), the Work Group proposed vaccine allocation for Phases 1b and 1c. A description of the population groups in these phases, supporting scientific data, consideration of ethical principles, and considerations for vaccination program implementation are presented in this report, and supporting evidence is available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19/evidence-table-phase-1b-1c.html.

Phase 1b

Approximately 49 million persons, including frontline essential workers (non–health care workers) and persons aged ≥75 years are recommended to receive vaccine in Phase 1b of the COVID-19 vaccination program (Table). Essential workers perform duties across critical infrastructure sectors and maintain the services and functions that U.S. residents depend on daily. The Cybersecurity and Infrastructure Security Agency (CISA) of the U.S. Department of Homeland Security has developed a list intended to guide jurisdictions in identifying essential critical infrastructure workers, who may be exempted during stay-at-home-orders (). ACIP used CISA guidance to define frontline essential workers as the subset of essential workers likely at highest risk for work-related exposure to SARS-CoV-2, the virus that causes COVID-19, because their work-related duties must be performed on-site and involve being in close proximity (<6 feet) to the public or to coworkers. ACIP has classified the following non–health care essential workers as frontline workers: first responders (e.g., firefighters and police officers), corrections officers, food and agricultural workers, U.S. Postal Service workers, manufacturing workers, grocery store workers, public transit workers, and those who work in the education sector (teachers and support staff members) as well as child care workers. A tiered approach for essential workers builds on the occupations identified by the National Academies of Science, Engineering and Medicine for early vaccination ().
TABLE

Advisory Committee on Immunization Practices recommendations for allocation of COVID-19 vaccines to persons aged ≥16 years — United States, December 2020

PhaseGroups recommended to receive COVID-19 vaccineNo. (millions)
Total persons in each group*Unique persons in each groupUnique persons in each phase
1a
Health care personnel
21
21
24
Long-term care facility residents
3
3
1b
Frontline essential workers§
30
30
49
Persons aged ≥75 years
21
19
1c
Persons aged 65–74 years
32
28
129
Persons aged 16–64 years with high-risk medical conditions
110
81
Essential workers§ not recommended for vaccination in Phase 1b
57
20
2All persons aged ≥16 years not previously recommended for vaccinationAll remainingAll remainingAll remaining

Abbreviation: COVID-19 = coronavirus disease 2019.

* Data sources for each group: health care personnel (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); long-term care facility residents (Minimum Data Set. Centers for Medicare & Medicaid Services; https://data.cms.gov/); frontline and other essential workers (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); age-specific groups (U.S. Census; https://data.census.gov/cedsci/); high-risk medical conditions (Behavioral Risk Factors Surveillance System, 2018; https://www.cdc.gov/brfss/annual_data/annual_data.htm).

† Excludes persons who were recommended to receive vaccine in an earlier phase (e.g., persons aged 65–74 years who are living in long-term care facilities or who are health care personnel, who would have been included in Phase 1a) and accounting for overlap between groups within the same phase (e.g., essential workers with high risk medical conditions).

§ Estimates for frontline and other essential workers are approximate and derived from prepandemic survey data; relative proportions will vary by state.

¶ As of December 18, only the Pfizer-BioNTech COVID-19 vaccine is authorized for use in persons aged 16–17 years.

Abbreviation: COVID-19 = coronavirus disease 2019. * Data sources for each group: health care personnel (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); long-term care facility residents (Minimum Data Set. Centers for Medicare & Medicaid Services; https://data.cms.gov/); frontline and other essential workers (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); age-specific groups (U.S. Census; https://data.census.gov/cedsci/); high-risk medical conditions (Behavioral Risk Factors Surveillance System, 2018; https://www.cdc.gov/brfss/annual_data/annual_data.htm). † Excludes persons who were recommended to receive vaccine in an earlier phase (e.g., persons aged 65–74 years who are living in long-term care facilities or who are health care personnel, who would have been included in Phase 1a) and accounting for overlap between groups within the same phase (e.g., essential workers with high risk medical conditions). § Estimates for frontline and other essential workers are approximate and derived from prepandemic survey data; relative proportions will vary by state. ¶ As of December 18, only the Pfizer-BioNTech COVID-19 vaccine is authorized for use in persons aged 16–17 years. Although there is no national surveillance for COVID-19 among frontline or other essential workers, reports of high incidence and outbreaks within multiple critical infrastructure sectors illustrate the COVID-19 risk in these populations and the disproportionate impact of COVID-19 on workers who belong to racial and ethnic minority groups. During March–June, for example, the Utah Department of Heath reported 1,389 COVID-19 cases associated with workplace outbreaks in 15 industry sectors, accounting for 12% of all COVID-19 cases in Utah during the same period (). In addition, despite representing 24% of Utah workers in all affected sectors, Hispanic and non-White workers accounted for 73% of COVID-19 cases in workplace-associated outbreaks (). Among 23 states reporting COVID-19 outbreaks in meat and poultry processing facilities during April and May, 16,233 outbreak-associated cases were reported from 239 facilities, including 86 COVID-19–related deaths (). The percentage of workers with COVID-19 ranged from 3% to 25% per facility, and among cases with information on race and ethnicity reported, 87% occurred among workers from racial or ethnic minority groups (). Persons aged ≥75 years are at high risk for COVID-19–associated morbidity and mortality. As of December 20, 2020, the cumulative incidence of COVID-19 among persons in this age group was 3,839 per 100,000 persons, with a cumulative hospitalization rate of 1,211 per 100,000, and a mortality rate of 719 per 100,000 (–). The overall proportion of persons aged ≥75 years who live in a multigenerational household is 6%; the proportion among non-Hispanic White persons is 4%, and the proportion among racial or ethnic minority groups is higher (non-Hispanic Black persons, 10%; Hispanic or Latino persons, 18%; non-Hispanic persons of other races, 20%).***

Phase 1c

In Phase 1c, vaccine should be offered to persons aged 65–74 years, persons aged 16–64 years with medical conditions that increase the risk for severe COVID-19, and essential workers not previously included in Phase 1a or 1b. Approximately 129 million persons are included in Phase 1c (Table), accounting for the overlap between groups in Phase 1c and earlier phases; for example, some adults aged 65–74 years reside in long-term care facilities, and many essential workers have high-risk medical conditions. Persons aged 65–74 years are at high risk for COVID-19–associated morbidity and mortality. As of December 20, 2020, the cumulative COVID-19 incidence in this age group was 3,109 per 100,000 persons, with a cumulative hospitalization rate of 642 per 100,000, and a mortality rate of 188 per 100,000 (–). Based on ongoing review of the literature, CDC has identified medical conditions or risk behaviors that are associated with increased risk for severe COVID-19. The risk for COVID-19–associated hospitalization increases with the number of high-risk medical conditions, from 2.5 times the risk for hospitalization for persons with one condition to 5 times the risk for those with three or more conditions (). According to a recent analysis of 2018 Behavioral Risk Factor Surveillance System data, at least 56% of persons aged 18–64 years report at least one high-risk medical condition (CDC COVID-19 Response Team, Division of Population Health, personal communication, December 2020). Essential worker sectors recommended for vaccination in Phase 1c include those in transportation and logistics, water and wastewater, food service, shelter and housing (e.g., construction), finance (e.g., bank tellers), information technology and communications, energy, legal, media, public safety (e.g., engineers), and public health workers.**** ACIP’s ethical principles for allocating initial supplies of COVID-19 vaccine, namely, to maximize benefits and minimize harms, promote justice, and mitigate health inequities (), support the allocation scheme for Phases 1b and 1c. Allocation of COVID-19 vaccine to essential workers and persons at increased risk for severe COVID-19 disease balances the vaccination program priorities of minimizing societal disruption and preventing morbidity and mortality. Essential workers constitute a large and heterogenous group. Allocation of vaccine to frontline essential workers in Phase 1b acknowledges their increased risk for occupational exposure compared with other essential worker categories, as well as the benefits to society of maintaining these essential functions. Allocation to persons aged ≥75 years is supported by their high risk for COVID-19–associated morbidity and mortality and is anticipated to also reduce hospitalizations in this group, easing the burden on strained health care systems. Populations included in Phase 1c are either at an increased risk for severe COVID-19 compared with the general population or support ongoing critical infrastructure operations. In addition, certain essential worker groups have high proportions of some racial and ethnic minority groups who have experienced disproportionate COVID-19 incidence, morbidity, and mortality (). Implementing vaccination programs to reach essential workers will pose challenges. Use of multiple strategies is recommended to reduce barriers to vaccination, such as providing vaccination opportunities at or close to the workplace. State and local health authorities will need to take local COVID-19 epidemiology and demand for vaccine into account when deciding to proceed to the next phase or to subprioritize within an allocation phase if necessary. A flexible approach to allocation will facilitate efficient management and ensure that COVID-19 vaccine is administered equitably and without delay. Additional interim considerations for phased implementation of COVID-19 vaccines are available at https://www.cdc.gov/vaccines/covid-19/initial-populations.html and https://www.cdc.gov/vaccines/covid-19/phased-implementation.html.

Phase 2

Phase 2 includes all other persons aged ≥16 years not already recommended for vaccination in Phases 1a, 1b, or 1c. Currently, in accordance with recommended age and conditions of use (), any authorized COVID-19 vaccine may be used. ACIP is closely monitoring clinical trials in children and adolescents and will consider recommendations for use when a COVID-19 vaccine is authorized for use in persons aged <16 years.

What is already known about this topic?

On December 1, the Advisory Committee on Immunization Practices (ACIP) recommended that health care personnel and long-term care facility residents be offered COVID-19 vaccination first (Phase 1a).

What is added by this report?

On December 20, ACIP updated interim vaccine allocation recommendations. In Phase 1b, COVID-19 vaccine should be offered to persons aged ≥75 years and non–health care frontline essential workers, and in Phase 1c, to persons aged 65–74 years, persons aged 16–64 years with high-risk medical conditions, and essential workers not included in Phase 1b.

What are the implications for public health practice?

Federal, state, and local jurisdictions should use this guidance for COVID-19 vaccination program planning and implementation.
  5 in total

1.  Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System.

Authors:  Jean Y Ko; Melissa L Danielson; Machell Town; Gordana Derado; Kurt J Greenlund; Pam Daily Kirley; Nisha B Alden; Kimberly Yousey-Hindes; Evan J Anderson; Patricia A Ryan; Sue Kim; Ruth Lynfield; Salina M Torres; Grant R Barney; Nancy M Bennett; Melissa Sutton; H Keipp Talbot; Mary Hill; Aron J Hall; Alicia M Fry; Shikha Garg; Lindsay Kim
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

2.  The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.

Authors:  Kathleen Dooling; Nancy McClung; Mary Chamberland; Mona Marin; Megan Wallace; Beth P Bell; Grace M Lee; H Keipp Talbot; José R Romero; Sara E Oliver
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-12-11       Impact factor: 17.586

3.  The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.

Authors:  Nancy McClung; Mary Chamberland; Kathy Kinlaw; Dayna Bowen Matthew; Megan Wallace; Beth P Bell; Grace M Lee; H Keipp Talbot; José R Romero; Sara E Oliver; Kathleen Dooling
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-11-27       Impact factor: 17.586

4.  Update: COVID-19 Among Workers in Meat and Poultry Processing Facilities - United States, April-May 2020.

Authors:  Michelle A Waltenburg; Tristan Victoroff; Charles E Rose; Marilee Butterfield; Rachel H Jervis; Kristen M Fedak; Julie A Gabel; Amanda Feldpausch; Eileen M Dunne; Connie Austin; Farah S Ahmed; Sheri Tubach; Charles Rhea; Anna Krueger; David A Crum; Johanna Vostok; Michael J Moore; George Turabelidze; Derry Stover; Matthew Donahue; Karen Edge; Bernadette Gutierrez; Kelly E Kline; Nichole Martz; James C Rajotte; Ernest Julian; Abdoulaye Diedhiou; Rachel Radcliffe; Joshua L Clayton; Dustin Ortbahn; Jason Cummins; Bree Barbeau; Julia Murphy; Brandy Darby; Nicholas R Graff; Tia K H Dostal; Ian W Pray; Courtney Tillman; Michelle M Dittrich; Gail Burns-Grant; Sooji Lee; Alisa Spieckerman; Kashif Iqbal; Sean M Griffing; Alicia Lawson; Hugh M Mainzer; Andreea E Bealle; Erika Edding; Kathryn E Arnold; Tomas Rodriguez; Sarah Merkle; Kristen Pettrone; Karen Schlanger; Kristin LaBar; Kate Hendricks; Arielle Lasry; Vikram Krishnasamy; Henry T Walke; Dale A Rose; Margaret A Honein
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-07-10       Impact factor: 17.586

5.  Racial and Ethnic Disparities Among COVID-19 Cases in Workplace Outbreaks by Industry Sector - Utah, March 6-June 5, 2020.

Authors:  David P Bui; Keegan McCaffrey; Michael Friedrichs; Nathan LaCross; Nathaniel M Lewis; Kylie Sage; Bree Barbeau; Dede Vilven; Carolyn Rose; Sara Braby; Sarah Willardson; Amy Carter; Christopher Smoot; Andrea Winquist; Angela Dunn
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-08-21       Impact factor: 17.586

  5 in total
  118 in total

1.  A Data Driven Approach for Prioritizing COVID-19 Vaccinations in the Midwestern United States.

Authors:  Greg Arling; Matthew Blaser; Michael D Cailas; John R Canar; Brian Cooper; Joel Flax-Hatch; Peter J Geraci; Kristin M Osiecki; Apostolis Sambanis
Journal:  Online J Public Health Inform       Date:  2021-03-12

2.  Assessment of COVID-19 Vaccination Practices for 16 Vaccination Providers in Puerto Rico, 2021.

Authors:  Liliana Sánchez-González; Joshua M Wong; Alexandra Conde; Marilyn Alicea; Eunice Soto-Gomez; Carla Feliciano; Ángel Rivera; Milton Martínez; Gabriela Paz-Bailey; Iris Cardona
Journal:  P R Health Sci J       Date:  2021-12       Impact factor: 0.705

3.  Vaccine and the Need To Be Heard: Considerations for COVID-19 Immunization in ESKD.

Authors:  Vesh Srivatana; Caroline Wilkie; Jeffery Perl; Suzanne Watnick
Journal:  Kidney360       Date:  2021-04-08

Review 4.  EBCOG position statement on COVID-19 vaccination for pregnant and breastfeeding women.

Authors:  Inês Martins; Frank Louwen; Diogo Ayres-de-Campos; Tahir Mahmood
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2021-05-14       Impact factor: 2.435

5.  Adults Hospitalized With Coronavirus Disease 2019 (COVID-19)-United States, March-June and October-December 2020: Implications for the Potential Effects of COVID-19 Tier-1 Vaccination on Future Hospitalizations and Outcomes.

Authors:  Samira Sami; Mark W Tenforde; H Keipp Talbot; Christopher J Lindsell; Jay S Steingrub; Nathan I Shapiro; Adit A Ginde; David J Douin; Matthew E Prekker; Heidi L Erickson; Samuel M Brown; Ithan D Peltan; Michelle N Gong; Akram Khan; Matthew C Exline; D Clark Files; Kevin W Gibbs; Todd W Rice; Jonathan D Casey; Carlos G Grijalva; William B Stubblefield; Kelsey N Womack; David N Hager; Nida Qadir; Steven Y Chang; Daniel J Henning; Jennifer G Wilson; Wesley H Self; Manish M Patel
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

6.  COVID-19 Vaccine Hesitancy and Its Determinants Among Adults with a History of Tobacco or Marijuana Use.

Authors:  Yong Yang; Aram Dobalian; Kenneth D Ward
Journal:  J Community Health       Date:  2021-05-06

7.  Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.

Authors:  Tamara Pilishvili; Katherine E Fleming-Dutra; Jennifer L Farrar; Ryan Gierke; Nicholas M Mohr; David A Talan; Anusha Krishnadasan; Karisa K Harland; Howard A Smithline; Peter C Hou; Lilly C Lee; Stephen C Lim; Gregory J Moran; Elizabeth Krebs; Mark Steele; David G Beiser; Brett Faine; John P Haran; Utsav Nandi; Walter A Schrading; Brian Chinnock; Daniel J Henning; Frank LoVecchio; Joelle Nadle; Devra Barter; Monica Brackney; Amber Britton; Kaytlynn Marceaux-Galli; Sarah Lim; Erin C Phipps; Ghinwa Dumyati; Rebecca Pierce; Tiffanie M Markus; Deverick J Anderson; Amanda K Debes; Michael Lin; Jeanmarie Mayer; Hilary M Babcock; Nasia Safdar; Marc Fischer; Rosalyn Singleton; Nora Chea; Shelley S Magill; Jennifer Verani; Stephanie Schrag
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-05-21       Impact factor: 35.301

8.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination.

Authors:  Nicola P Klein; Ned Lewis; Kristin Goddard; Bruce Fireman; Ousseny Zerbo; Kayla E Hanson; James G Donahue; Elyse O Kharbanda; Allison Naleway; Jennifer Clark Nelson; Stan Xu; W Katherine Yih; Jason M Glanz; Joshua T B Williams; Simon J Hambidge; Bruno J Lewin; Tom T Shimabukuro; Frank DeStefano; Eric S Weintraub
Journal:  JAMA       Date:  2021-10-12       Impact factor: 56.272

9.  COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors.

Authors:  Austin R Waters; Deanna Kepka; Joemy M Ramsay; Karely Mann; Perla L Vaca Lopez; John S Anderson; Judy Y Ou; Heydon K Kaddas; Alexandra Palmer; Nicole Ray; Tomoko Tsukamoto; Douglas B Fair; Mark A Lewis; Anne C Kirchhoff; Echo L Warner
Journal:  JNCI Cancer Spectr       Date:  2021-06-29

10.  mRNA Covid-19 Vaccines in Pregnant Women.

Authors:  Laura E Riley
Journal:  N Engl J Med       Date:  2021-06-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.